MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 316-324

  Erskine, Courtney L ^a   Krco, Christopher J ^a   Hedin, Karen E ^a   Borson, Nancy D ^b   Kalli, Kimberly R ^b   Behrens, Marshall D ^a   Heman Ackah, Sabrina M ^a   Von Hofe, Eric ^c   Wettstein, Peter J ^b   Mohamadzadeh, Mansour ^d   Knutson, Keith L ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c Antigen Express Inc   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FOLATE RECEPTOR 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HELPER CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION;

AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; FOLATE RECEPTOR 1; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 79960425151     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100658     Document Type: Article

References (40)

1. Knutson, K. L., and M. L. Disis. 2005. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54: 721-728.
2. Zhu, J., H. Yamane, and W. E. Paul. 2010. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28: 445-489.
3. Crome, S. Q., A. Y. Wang, and M. K. Levings. 2010. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin. Exp. Immunol. 159: 109-119.
4. Disis, M. L., T. A. Gooley, K. Rinn, D. Davis, M. Piepkorn, M. A. Cheever, K. L. Knutson, and K. Schiffman. 2002. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20: 2624-2632.
5. Knutson, K. L., K. Schiffman, and M. L. Disis. 2001. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107: 477-484.
6. Fonseca, D. P., B. Benaissa-Trouw, M. van Engelen, C. A. Kraaijeveld, H. Snippe, and A. F. Verheul. 2001. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein. Infect. Immun. 69: 4839-4845.
7. Lu, J., Y. Higashimoto, E. Appella, and E. Celis. 2004. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J. Immunol. 172: 4575-4582. (Pubitemid 38375275)
8. González, P. A., L. J. Carreño, D. Coombs, J. E. Mora, E. Palmieri, B. Goldstein, S. G. Nathenson, and A. M. Kalergis. 2005. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc. Natl. Acad. Sci. USA 102: 4824-4829.
9. Adams, S., and R. E. Humphreys. 1995. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur. J. Immunol. 25: 1693-1702.
10. Kelemen, L. E. 2006. The role of folate receptor a in cancer development, progression and treatment: cause, consequence or innocent bystander? Int. J. Cancer 119: 243-250.
11. Kallinteris, N. L., S. Wu, X. Lu, R. E. Humphreys, E. von Hofe, and M. Xu. 2005. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100 (48-58) MHC class II epitope. J. Immunother. 28: 352-358.
12. Chou, C. L., S. Mirshahidi, K. W. Su, A. Kim, K. Narayan, S. Khoruzhenko, M. Xu, and S. Sadegh-Nasseri. 2008. Short peptide sequences mimic HLA-DM functions. Mol. Immunol. 45: 1935-1943.
13. Malcherek, G., C. Wirblich, N. Willcox, H. G. Rammensee, J. Trowsdale, and A. Melms. 1998. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur. J. Immunol. 28: 1524-1533.
14. Humphreys, R. E., S. Adams, G. Koldzic, B. Nedelescu, E. von Hofe, and M. Xu. 2000. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 18: 2693-2697. (Pubitemid 30211577)
15. Holmes, J. P., L. C. Benavides, J. D. Gates, M. G. Carmichael, M. T. Hueman, E. A. Mittendorf, J. L. Murray, A. Amin, D. Craig, E. von Hofe, et al. 2008. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26: 3426-3433.
16. Curiel, T. J., C. Morris, M. Brumlik, S. J. Landry, K. Finstad, A. Nelson, V. Joshi, C. Hawkins, X. Alarez, A. Lackner, and M. Mohamadzadeh. 2004. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J. Immunol. 172: 7425-7431. (Pubitemid 38747604)
17. Knutson, K. L., B. Almand, Y. Dang, and M. L. Disis. 2004. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 64: 1146-1151.
18. Kallinteris, N. L., D. M. Powell, C. E. Blackwell, M. C. Kim, X. Lu, S. Wu, R. E. Humphreys, M. Xu, and E. von Hofe. 2006. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front. Biosci. 11: 46-58.
19. Knutson, K. L., C. J. Krco, C. L. Erskine, K. Goodman, L. E. Kelemen, P. J. Wettstein, P. S. Low, L. C. Hartmann, and K. R. Kalli. 2006. T-cell immunity to the folate receptor a is prevalent in women with breast or ovarian cancer. J. Clin. Oncol. 24: 4254-4261.
20. Behrens, M. D., W. M. Wagner, C. J. Krco, C. L. Erskine, K. R. Kalli, J. Krempski, E. A. Gad, M. L. Disis, and K. L. Knutson. 2008. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 111: 1472-1479.
21. Knutson, K. L., Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, and M. L. Disis. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177: 84-91.
22. Wettstein, P. J., M. Strausbauch, T. Therneau, and N. Borson. 2008. The application of real-time PCR to the analysis of T cell repertoires. Nucleic Acids Res. 36: e140.
23. + T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 195: 1407-1418.
24. Gillogly, M. E., N. L. Kallinteris, M. Xu, J. V. Gulfo, R. E. Humphreys, and J. L. Murray. 2004. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol. Immunother. 53: 490-496.
25. Matza, D., A. Kerem, and I. Shachar. 2003. Invariant chain, a chain of command. Trends Immunol. 24: 264-268. (Pubitemid 36555966)
26. Matza, D., A. Kerem, H. Medvedovsky, F. Lantner, and I. Shachar. 2002. Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity 17: 549-560. (Pubitemid 35351501)
27. Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E. E. Bates, G. Trinchieri, C. Caux, and P. Garrone. 2005. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201: 1435-1446.
28. + T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
29. + T cells following peptide vaccination. J. Immunol. 176: 6340-6346.
30. Hackl, D., J. Loschko, T. Sparwasser, W. Reindl, and A. B. Krug. 2011. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur. J. Immunol. 41: 1334-1343 .
31. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
32. + regulatory T cells. Proc. Natl. Acad. Sci. USA 105: 18460-18465.
33. McKeithan, T. W. 1995. Kinetic proofreading in T-cell receptor signal transduction. Proc. Natl. Acad. Sci. USA 92: 5042-5046.
34. + T cells. J. Immunol. 180: 8386-8392.
35. + T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79: 11457-11466.
36. Campanella, G. S., B. D. Medoff, L. A. Manice, R. A. Colvin, and A. D. Luster. 2008. Development of a novel chemokine-mediated in vivo T cell recruitment assay. J. Immunol. Methods 331: 127-139.
37. Rubio, N., and F. Sanz-Rodriguez. 2007. Induction of the CXCL1 (KC) chemokine in mouse astrocytes by infection with the murine encephalomyelitis virus of Theiler. Virology 358: 98-108. (Pubitemid 46048868)
38. Kumar, A., T. D. Humphreys, K. N. Kremer, P. S. Bramati, L. Bradfield, C. E. Edgar, and K. E. Hedin. 2006. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity 25: 213-224.
39. + regulatory T cells. J. Immunol. 185: 174-182.
40. Yang, J., M. O. Brook, M. Carvalho-Gaspar, J. Zhang, H. E. Ramon, M. H. Sayegh, K. J. Wood, L. A. Turka, and N. D. Jones. 2007. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. USA 104: 19954-19959.